NCT07174401Not yet recruitingPhase 4
Rocklatan Retinal Perfusion OCT Study
Rocklatan Trial With Optical Coherence Tomography Study of Retinal Perfusion
Source: ClinicalTrials.gov · Last updated 24 Dec 2025
Brief summary (registry, in English)
The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 12 Sept 2025
- Start date
- Jan 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Oregon Health and Science University
- Diseases
- Glaucoma
- NCT number
- NCT07174401
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 30
- From Jan 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Eye disease that could affect VF, NFL thickness, or NFLP (e.g., visually significant cataract, AMD, diabetic retinopathy, and optic neuropathy) at any study visit
Age
- Age \< 21 years at baseline
Other
- Best corrected visual acuity worse than 20/30 on chart review of most recent clinic visit
- OCT and OCTA scans not meeting quality criteria at baseline
- Inability to cooperate with study procedures
- Inability to commit to the study visits
Who the study is looking for
- Patients with both eyes with open angle glaucoma.
- Abnormal VF (glaucomatous pattern with PSD abnormal at p\<0.05 or GHT outside normal limits) on most recent two clinic visits on chart review
- Glaucomatous disc abnormality on chart review and confirmed on baseline disc photograph
- Overall average NFL thickness \> 55 μm measured by Heidelberg Spectralis OCT -Glaucoma Module Premium Edition (chart review), consistent with early glaucoma
- NFLP-CD deficit (below 5 percentile of normal) in any of the 8 sectors on the initial baseline visit
- The difference in baseline NFLP-CD between the left and right eye should be less than 5% (% of area).
- IOP \>= 17 mm Hg on the most recent two clinic visits (chart review) after monotherapy with latanoprost in both eyes.
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Casey Eye Institute, Oregon Health & Science University Coordinator of this site? Confirm its status | Portland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.